OVERALL ABSTRACT Founded in 1977 by John Mendelsohn, the Cancer Center at University of California San Diego (UCSD) has been continuously funded by the NCI Cancer Center Support Grant (CCSG) since 1978 and has held Comprehensive status since 2001. As the only NCI-designated Comprehensive Cancer Center in San Diego County, the mission of Moores Cancer Center (MCC) is to reduce the impact of cancer in the region and beyond by fostering scientific discovery, research training, and interdisciplinary care. Our goal is to create, translate, and deliver high-impact discoveries and innovations in cancer prevention and care through a deep understanding of the needs of the catchment area, and prepare the next generation of cancer researchers. Accordingly, MCC?s aims are to: 1) Elucidate the biology of cancer and catalyze trans-disciplinary team science across the science spectrum; 2) Develop and test innovative preventive, diagnostic, and therapeutic approaches; 3) Conduct cancer prevention and control research to reduce cancer disparities in vulnerable populations; 4) Provide underrepresented minorities with access to cutting edge multi-disciplinary care; 5) Provide training and education across the trainee continuum; and 6) Develop and implement community-based cancer education and outreach programs. To this end, MCC brings together 232 members from 5 UCSD Schools (Medicine, Engineering, Pharmacy and Pharmaceutical Sciences, Physical Sciences and Biological Sciences) and 2 consortium partners (one existing: San Diego State University, and one new: La Jolla Institute). Furthermore, MCC integrates the resources of UCSD Health Sciences and its affiliated hospitals in the UCSD Health System for a unified approach to cancer research and clinical care. MCC fulfills its mission through the activities of its 5 Research Programs (Cancer Biology and Signaling, Structural and Functional Genomics, Solid Tumor Therapeutics, Hematological Malignancies, and Cancer Control) that are supported by 7 Shared Resources (Flow Cytometry, Microscopy, Transgenic Mouse, Biostatistics, Genomics and Computational Biology, Biorepository and Tissue Technology, and Biobehavioral), and infrastructure provided by Community Outreach, Training and Education, Clinical Protocol and Data Management, and Protocol Review and Monitoring. Under the leadership of Dr. Scott Lippman, Center Director and Associate Vice- Chancellor for Cancer Research and Care, MCC has seen tremendous growth. During the project period, MCC members authored 3931 cancer-relevant research articles, and in 2017 were supported by $128.2 million (DC) in annual cancer-relevant peer-reviewed funding (8% increase); and the total annualized cancer-relevant research base was $148.5M, an increase of 11% from the previous project period by lateral comparison. Collaborative peer-reviewed grant funding also increased from annual total costs of $65.9M in 2013 to $69.9M in 2017 (6% increase). Importantly, 33 of MCC?s scientific discoveries were translated to the clinic through 41 investigator-initiated clinical trials, a 14-fold increase from the previous project period.

Public Health Relevance

OVERALL NARRATIVE MCC?s mission is to reduce the impact of cancer to the catchment area and beyond by discovering, translating, and delivering high-impact innovations in interdisciplinary cancer prevention and care, and prepare the next generation of cancer researchers. The CCSG provides critical infrastructure to support the research necessary to achieve our mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023100-33
Application #
9703583
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Belin, Precilla L
Project Start
1996-07-01
Project End
2024-04-30
Budget Start
2019-05-28
Budget End
2020-04-30
Support Year
33
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Huang, Justin K; Carlin, Daniel E; Yu, Michael Ku et al. (2018) Systematic Evaluation of Molecular Networks for Discovery of Disease Genes. Cell Syst 6:484-495.e5
Kalyanaraman, Hema; Schwaerzer, Gerburg; Ramdani, Ghania et al. (2018) Protein Kinase G Activation Reverses Oxidative Stress and Restores Osteoblast Function and Bone Formation in Male Mice With Type 1 Diabetes. Diabetes 67:607-623
Hartman, Sheri J; Marinac, Catherine R; Cadmus-Bertram, Lisa et al. (2018) Sedentary Behaviors and Biomarkers Among Breast Cancer Survivors. J Phys Act Health 15:1-6
Wu, Yan; Tamayo, Pablo; Zhang, Kun (2018) Visualizing and Interpreting Single-Cell Gene Expression Datasets with Similarity Weighted Nonnegative Embedding. Cell Syst 7:656-666.e4
Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888
Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306
Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135
Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42
Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593
Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69

Showing the most recent 10 out of 862 publications